Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.

Makoto Nishio,Kazuhiko Nakagawa,Tetsuya Mitsudomi,Nobuyuki Yamamoto,Tomohiro Tanaka,Hiroshi Kuriki,Ali Zeaiter,Tomohide Tamura

Lung Cancer（2018）

引用 63|浏览8

暂无评分

摘要

•Alectinib is the preferred first-line treatment option for ALK-positive NSCLC.•Alectinib showed superior efficacy to crizotinib in the J-ALEX phase III study.•We assessed CIRs of CNS progression, non-CNS progression and death in J-ALEX.•Alectinib prevented CNS progression in patients with baseline CNS disease.•Alectinib prevented onset of new CNS lesions in patients without baseline CNS disease.

查看译文

关键词

ALK,CI,CIR,CNS,CT,CTX,ECOG PS,HR,IRF,ITT,MRI,NCCN,NSCLC,RECIST,RT,RT-PCR

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要